...
首页> 外文期刊>Medicinal chemistry >Inhibition of Adipogenesis by Thiourea Derivatives
【24h】

Inhibition of Adipogenesis by Thiourea Derivatives

机译:硫脲衍生物抑制脂肪生成

获取原文
获取原文并翻译 | 示例

摘要

Background: Obesity is one of the major health problems with inherent risk of type 2diabetes, hypertension, CVDs, etc. Adipogenesis is a major contributor in the process of obesity.Inhibition of adipocytes differentiation is one of the key approaches to treat obesity.Objective: To discover the new inhibitors of adipogenesis as the treatment for obesity.Method: We describe here, the synthesis, and anti-adipogenic activity of thiourea derivatives 1-14.These derivatives were synthesized by the reactions of phenyl and pentafluorophenyl isothiocyanatewith different aromatic amines. Pure compounds 1-14 were evaluated for their in vitro antiadipogenesisactivity employing 3T3-L1 cells lines.Results: Compounds 1-3, 5-9, and 11-14 significantly inhibited the pre-adipocyte differentiationinto adipocytes, which was measured by staining the cells, and through morphological examination.Compound 10 (1-(4"-Chlorophenyl)-3-(pentafluorophenyl)-thiourea) showed a potent inhibitionof adipocyte differentiation with IC50 = 740.00 ± 2.36 nM, which was more potent than thestandards, epigallocatechin gallate (IC50 = 16.73 ± 1.34 μM), and curcumin (IC50 = 18.62 ± 0.74μM). All other compounds showed a moderate to weak anti-adipogenesis activity. Compounds 1-14 were also evaluated for their cytotoxicity. Compounds 3, 10, and 14 showed some toxicity tothe cancer cell lines, while compounds 2, 3, 10, 12, and 14 showed a moderate to weak cytotoxicityagainst the normal cell lines.Conclusion: All the compounds reported in this paper are known, except compound 11. They havebeen identified as new inhibitors of Adipogenesis. Adipogenesis is the process of adipocytes differentiationfrom pre-adipocytes. This extensively studied model of cell diff differentiation. Furthersynthetic modifications, and optimization of anti-adipogenic activity may lead to the developmentof anti-obesity agents.
机译:背景:肥胖是患有2型二胎,高血压,CVDS等固有风险的主要健康问题之一。肥胖是肥胖过程中的主要贡献者。抗脂肪细胞的差异是治疗肥胖症的关键方法之一。目的:为了发现脂肪生成的新抑制剂作为肥胖症的治疗方法。方法:我们在此描述,硫脲衍生物1-14的合成和抗脂肪发生活性。这些衍生物通过苯基和五氟苯基异硫氰酸酯的反应合成,不同的芳族胺。评价纯化合物1-14的体外抗肿瘤发生性,其采用3T3-L1细胞系。结果:化合物1-3,5-9和11-14显着抑制了通过染色细胞来测量的预脂肪细胞分化脂肪细胞,通过形态学检查.. POUND 10(1-(4“ - 氯苯基)-3-(五氟苯基)-Thiourea)显示脂肪细胞分化与IC50 = 740.00±2.36nm的有效抑制,这比审查更有效,EpigallocateChin gallate( IC50 = 16.73±1.34μm),姜黄素(IC50 = 18.62±0.74μm)。所有其他化合物显示出中等至弱抗脂肪发生活性。还评估其细胞毒性的化合物1-14。化合物3,10和14显示出一些毒性,而癌细胞系,而化合物2,3,10,12和14显示了正常细胞系的中等至弱细胞毒性。结论:本文报道的所有化合物都是已知的,除了化合物11。它们被鉴定作为脂肪发生的新抑制剂。脂肪生成是脂肪细胞分化的过程从前脂肪细胞的过程中。这种广泛研究的细胞差异分化模型。抗脂肪活性的脱脂修饰和优化可能导致抗肥胖剂的开发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号